How Organ transplantation Works

Every cell in your body displays unique surface proteins called human leukocyte antigens (HLA), which act like molecular fingerprints identifying "self" versus "foreign." These markers come in thousands of possible combinations inherited from your parents. When transplant surgeons match organs, they perform extensive blood tests to compare six major HLA proteins between donor and recipient, seeking the closest possible match.

The better the HLA match, the less likely the recipient's immune system will recognize the transplanted organ as an invader. A perfect six-out-of-six match occurs most commonly between identical twins, but even siblings share on average only three markers. Unrelated donors rarely match more than two or three HLA proteins, which is why transplant recipients typically need lifelong medication to suppress immune attacks.

Beyond HLA typing, transplant teams also match ABO blood groups just as they would for blood transfusions. If a Type A recipient receives a Type B organ, antibodies already circulating in their blood would immediately attack the transplanted tissue, causing hyperacute rejection within minutes to hours. This makes finding compatible donors especially challenging for patients with rare blood types or highly sensitized immune systems from prior transplants or pregnancies.

When surgeons remove an organ from a donor, they immediately flush it with cold preservation solution—a special fluid containing nutrients, electrolytes, and substances that reduce cellular swelling and slow metabolism. This cold flush removes the donor's blood and rapidly cools the organ to around 4°C (39°F), which dramatically slows down the cellular processes that require oxygen. At these cold temperatures, cells enter a state resembling hibernation, reducing their energy needs to about 5% of normal.

The preserved organ is then placed in sterile bags filled with more preservation solution and packed in ice inside coolers for transport. Different organs tolerate this cold storage for different durations: hearts and lungs remain viable for only 4-6 hours, livers for 12-18 hours, and kidneys for up to 36 hours. Beyond these windows, cells begin dying from lack of oxygen and nutrient delivery, making the organ unsuitable for transplantation.

Researchers have recently developed machine perfusion devices that pump oxygenated preservation fluid through the organ's blood vessels during transport, essentially keeping it "breathing" outside the body. These devices can extend preservation times and even improve organ quality by providing continuous oxygen and nutrients. Some systems warm organs to body temperature, allowing surgeons to assess organ function in real-time before transplantation.

The transplanted organ dies without blood flow, so surgeons must meticulously reconnect the donor's blood vessels to the recipient's circulatory system using microsurgical techniques. For a kidney transplant, this means stitching the donor renal artery (often just 5-7 millimeters wide) to the recipient's iliac artery using sutures finer than human hair. Each stitch must be perfectly placed to create a watertight seal that can withstand arterial blood pressure without leaking or clotting.

The anastomosis—the surgical connection between vessels—requires extreme precision because even small errors have catastrophic consequences. If stitches are too tight, they can narrow the vessel opening and restrict blood flow; too loose, and blood leaks into surrounding tissues. Surgeons work under magnification, placing 20-30 individual sutures in a circular pattern around each vessel junction, ensuring the inner linings (endothelium) of donor and recipient vessels align smoothly.

After connecting arteries that bring oxygenated blood into the organ, surgeons then attach veins that drain blood back to the heart, and finally connect any necessary ducts like bile ducts in liver transplants or ureters in kidney transplants. When clamps are released and blood flows through the newly connected vessels, the surgical team watches carefully for the organ to "pink up" as oxygenated blood perfuses the tissue—a critical moment called reperfusion that signals successful vascular connection.

The human immune system evolved to identify and destroy anything foreign, which means it naturally recognizes a transplanted organ as an invader to be eliminated. To prevent this rejection, recipients must take immunosuppressive medications that interfere with different stages of the immune response. Calcineurin inhibitors like tacrolimus block the activation of T-cells—the immune system's search-and-destroy specialists that would normally coordinate attacks on foreign tissue.

Transplant recipients typically take a combination of three or more immunosuppressants working through different mechanisms to create overlapping protection. Antimetabolites like mycophenolate prevent immune cells from multiplying, while corticosteroids dampen overall immune inflammation. This multi-drug approach allows lower doses of each medication, reducing side effects while maintaining sufficient immune suppression to protect the transplanted organ.

The challenge lies in finding the right balance: too much immunosuppression leaves patients vulnerable to infections and cancers that a healthy immune system would normally eliminate, while too little allows rejection to begin. Transplant physicians monitor drug levels through frequent blood tests and adjust doses based on both laboratory values and clinical signs of rejection, such as rising creatinine levels indicating kidney dysfunction or abnormal liver enzymes.

Despite medication, rejection episodes still occur in 10-30% of transplant recipients during the first year. Acute rejection happens when the immune system mounts a sudden attack on the transplanted organ, causing inflammation and tissue damage. Physicians treat these episodes with high-dose steroids or powerful antibodies that temporarily wipe out specific immune cell populations, usually reversing the rejection if caught early through biopsy or monitoring.

Once transplanted and connected, the donor organ begins functioning in a completely different biological environment than where it developed. A transplanted kidney must immediately start filtering the recipient's blood chemistry, adjusting to different toxin levels, medication concentrations, and metabolic waste products. The organ's cells must respond to the recipient's hormones and neural signals, essentially learning a new chemical language to coordinate with systems like blood pressure regulation and fluid balance.

Over weeks to months, the transplanted organ undergoes remodeling as recipient cells gradually infiltrate and incorporate into the donor tissue. Blood vessels from the recipient grow into the transplanted organ in a process called neovascularization, creating additional circulation pathways beyond the surgically connected main vessels. Nerve connections may partially regenerate, though transplanted organs typically remain less sensitive to normal nerve signals—for example, heart transplant recipients don't feel angina chest pain during cardiac stress because sensory nerves don't fully reconnect.

The recipient's body also adapts to the new organ's presence through a process called accommodation, where the immune system gradually becomes more tolerant of the foreign tissue over time. While complete tolerance without immunosuppression remains rare, many long-term transplant recipients can eventually reduce their medication doses. The transplanted organ essentially becomes a hybrid structure—genetically donor tissue embedded in a network of recipient blood vessels and supporting cells, functioning as an integrated part of the recipient's physiology.